Table 2.
Association of clinical diagnosis and the immunohistochemical expression of PAX-8
| PAX 8 results no. (%) | Total no. 60 | P value | ||
|---|---|---|---|---|
| Positive | Negative | |||
| Cancer histological type | ||||
| SCC | 3 (6.7) | 42 (93.3) | 45 (75.0) | < 0.001 |
| Adenocarcinoma | 11 (73.3) | 4 (26.7) | 15 (25.0) | |
| Cancer site | ||||
| Cervix | 8 (15.7) | 43 (84.3) | 51 (85.0) | < 0.001 |
| Endometrium | 5 (100) | 0 (0.0) | 5 (8.3) | |
| Ovary | 1 (25.0) | 3 (75.0) | 4 (6.7) | |
| FIGO staging | ||||
| Stage 1 | 1 (33.3) | 2 (66.7) | 3 (5.0) | 0.034 |
| Stage 2A | 0 (0.0) | 6 (100) | 6 (10.0) | |
| Stage 2B | 3 (21.4) | 11 (78.6) | 14 (23.3) | |
| Stage 3A | 2 (25.0) | 6 (75.0) | 8 (13.3) | |
| Stage 3B | 2 (11.8) | 15 (88.2) | 17 (28.3) | |
| Stage 4A | 0 (0.0) | 3 (100) | 3 (5.0) | |
| Stage 4B | 6 (66.7) | 3 (33.3) | 9 (15.0) | |
| Cancer histopathological grading | ||||
| Well differentiated SCC | 0 (0.0) | 12 (100) | 12 (20.0) | < 0.001 |
| Poorly differentiated SCC | 2 (10.0) | 18 (90.0) | 20 (33.3) | |
| Moderately differentiated SCC | 1 (7.7) | 12 (92.3) | 13 (21.7) | |
| Endometrium adenocarcinoma | 9 (81.8) | 2 (18.2) | 11 (18.3) | |
| Endocervical adenocarcinoma | 1 (100) | 0 (0.0) | 1 (1.7) | |
| Metastatic adenocarcinoma | 0 (0.0) | 2 (100) | 2 (3.3) | |
| Ovarian mucinous cyst adenocarcinoma | 1 (100) | 0 (0.0) | 1 (1.7) | |
SCC Squamous Cell Carcinoma